We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oncimmune Holdings Plc | LSE:ONC | London | Ordinary Share | GB00BYQ94H38 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 21.00 | 20.60 | 21.80 | 21.00 | 21.00 | 21.00 | 12,949 | 11:04:46 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Medical Laboratories | 1.47M | -6.15M | -0.0830 | -2.53 | 15.57M |
TIDMONC
RNS Number : 1888A
Oncimmune Holdings PLC
21 September 2022
Oncimmune Holdings plc
("Oncimmune" or the "Company")
PDMR Dealing
Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, has been notified that Dr Adam Mark Hill, PDMR and Chief Executive Officer, today purchased 8,005 ordinary shares of GBP0.01 each in the Company ("Ordinary Shares") for GBP0.624599 per share.
Following this transaction, Dr Hill has a total interest in the Company of 73,872 Ordinary Shares, representing approximately 0.11 per cent of the Company's issued share capital of 69,475,480.
In addition, Dr Hill holds options over a total of 3,490,862 Ordinary Shares, representing approximately 5.02 per cent of the Company's issued share capital.
This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.
Notification and public disclosure of transactions by person discharging managerial responsibilities and persons closely associated with them:
Details of the person discharging managerial responsibilities 1 / person closely associated a) Name Dr Adam Mark Hill ------------------------------------- -------------------------------------- Reason for the notification 2 ----------------------------------------------------------------------------- a) Position/status Chief Executive Officer ------------------------------------- -------------------------------------- b) Initial notification Initial Notification /Amendment ------------------------------------- -------------------------------------- Details of the issuer, emission allowance market participant, 3 auction platform, auctioneer or auction monitor ----------------------------------------------------------------------------- a) Name Oncimmune Holdings plc ------------------------------------- -------------------------------------- b) LEI 213800HCYIWT6YPI1I02 ------------------------------------- -------------------------------------- Details of the transaction(s): section to be repeated 4 for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----------------------------------------------------------------------------- a) Description of the Ordinary Shares of GBP0.01 each financial instrument, type of instrument Identification code ISIN: GB00BYQ94H38 b) Nature of the transaction Purchase of Ordinary Shares ------------------------------------- -------------------------------------- c) Price(s) and volume(s) ------------------- -------------- Price(s) Volume(s) ------------------- -------------- GBP0.624599 8,005 -------------------------------------------------------------- -------------- d) Aggregated information N/A - single transaction - Aggregated volume - Price e) Date of the transaction 21 September 2022 ------------------------------------- -------------------------------------- f) Place of the transaction London Stock Exchange, AIMX ------------------------------------- --------------------------------------
For further information:
Oncimmune Holdings plc
Dr Adam M Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk
Singer Capital Markets (Nominated Adviser and Joint Broker)
Aubrey Powell, Harry Gooden, George Tzimas, James Fischer
+44 (0)20 7496 3000
WG Partners (Joint Broker)
David Wilson, Nigel Barnes, Erland Sternby
+44 (0)20 3705 9321
Investor Relations:
John Goold
IR@oncimmune.com
About Oncimmune
ImmunoINSIGHTS Service Business
Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. The ImmunoINSIGHTS service business leverages Oncimmune's technology platform and methodologies across multiple diseases, to offer life-science organizations actionable insights for therapies across the development and product lifecycle. Our core immune-profiling technology is underpinned by our library of over eight thousand immunogenic proteins, one of the largest of its kind. This helps identify trial participants and patients into clinically relevant subgroups, enabling development of targeted and more effective treatments.
Oncimmune's ImmunoINSIGHTS service business is based at the Company's discovery research centre in Dortmund, Germany. The business platform enables life science organizations to optimize drug development and delivery, leading to more effectively targeted and safer treatments for patients.
The ImmunoINSIGHTS development team is based in the US and Europe and Oncimmune is seeking to replicate the Dortmund facility in the US in the medium term.
EarlyCDT Product Business
Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to GBP3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programs, globally.
Oncimmune's diagnostic products business is located at its laboratory facility in Nottingham, UK.
For more information, visit www.oncimmune.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHUAAORUSUKUAR
(END) Dow Jones Newswires
September 21, 2022 09:16 ET (13:16 GMT)
1 Year Oncimmune Chart |
1 Month Oncimmune Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions